News Headlines Article

Big Pharma’s Delicate Dance on Drug Prices
The Wall Street Journal

Drug makers are enjoying a research-and-development revival after a fallow period. Last year the U.S. Food and Drug Administration approved 45 new drugs, more than double the number in 2006. But the industry also faces growing criticism of the prices it charges for new drugs — some cancer therapies cost as much as $150,000 a year — as well as repeated price increases for older drugs. Critics say high prices are putting drugs out of reach for many patients and straining health-care budgets.

Commands